The Conversation (0)
Helix BioPharma announced its financial results for the first quarter of their 2018 fiscal year.
Helix BioPharma (TSX:HBP) announced its financial results for the first quarter of their 2018 fiscal year.
As quoted in the press release:
FINANCIAL REVIEW
The Company recorded a net loss and total comprehensive loss of $2,303,000 ($0.02 loss per common share) and $3,287,000 ($0.04 loss per common share) for the three-month periods ended October 31, 2017 and 2016, respectively.
Research and development
Research and development costs for the three-month periods ended October 31, 2017 and 2016 totalled $1,764,000 and $2,268,000, respectively.
L-DOS47 research and development expenses for the three-month periods ended October 31, 2017 and 2016 totalled $1,482,000 and $1,765,000, respectively. L-DOS47 research and development expenditures relate primarily to the Company’s LDOS002 European Phase I/II clinical study in Poland and the LDOS001 U.S. Phase I clinical study in the U.S in addition to some preliminary expenditures related to the Company’s LDOS003 Phase II clinical study in Poland and the Ukraine that the Company plans to commence enrolment in early 2018.
Click here to read the full press release.
Source: www.marketwired.com